Skip To Main Content
Patricia Spilman on Muck Rack

Patricia Spilman

As seen in: Nature, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Patricia Spilman’s profile

Articles by Patricia Spilman

Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an esca…

|
By Gard Nelson, Oleksandr Buzko, Patricia Spilman, Kayvan R. Niazi
| BioRxiv
New Results Gard Nelson, Oleksandr Buzko, Patricia Spilman, Kayvan Niazi, Shahrooz Rabizadeh, View ORCID ProfilePatrick Soon-Shiong doi: https://doi.org/10.1101/2021.01.13.426558 Abstract Rapidly spreading SARS-CoV-2 variants present not only an increased threat to human health due to the confirmed greater transmissibility of several of these new strains but, due to conformational changes induced by the mutations, may render first-wave SARS-CoV-2 convalescent sera, vaccine-induced antibodies,...
Open in Who Shared Issue with article?

Millisecond-scale molecular dynamics simulation of spike RBD structure reveals evolutionary adaption of SARS-CoV-2 to stably bind ACE2

|
By Aaron Bassett, Patricia Spilman, Gard Nelson, Oleksandr Buzko
| BioRxiv
New Results Gard Nelson, Oleksandr Buzko, Aaron Bassett, Patricia Spilman, Kayvan Niazi, Shahrooz Rabizadeh, View ORCID ProfilePatrick Soon-Shiong doi: https://doi.org/10.1101/2020.12.11.422055 Abstract The Receptor Binding Domain (RBD) of the SARS-CoV-2 surface spike (S) protein interacts with host angiotensin converting enzyme 2 (ACE2) to gain entry to host cells and initiate infection1–3.
Open in Who Shared Issue with article?

A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer’s disease mouse model

|
By Dongsheng Bai, Jesus Campagna, Patricia Spilman, Barbara Jagodzinska
| Nature Verified
Abstract We describe here the results from the testing of a small molecule first-in-class apolipoprotein E4 (ApoE4)-targeted sirtuin1 (SirT1) enhancer, A03, that increases the levels of the neuroprotective enzyme SirT1 while not affecting levels of neurotoxic sirtuin 2 (SirT2) in vitro in ApoE4-transfected cells. A03 was identified by high-throughput screening (HTS) and found to be orally bioavailable and brain penetrant.
Open in Who Shared Issue with article?
Show More